Contribution to the pharmacokinetics of amitriptyline

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Metabolism

Background:

• Amitriptyline is a widely prescribed tricyclic antidepressant.
• Understanding its pharmacokinetic profile is crucial for optimizing therapeutic outcomes.
• First-pass metabolism significantly impacts drug bioavailability.

Purpose of the Study:

• To investigate the clinical pharmacokinetics of amitriptyline.
• To determine key pharmacokinetic parameters including half-life and first-pass metabolism.
• To assess the formation and levels of the active metabolite, nortriptyline.

Main Methods:

• Oral administration of 75 mg amitriptyline to four healthy volunteers.
• Measurement of plasma concentrations of amitriptyline and nortriptyline over time.
• Analysis of drug disappearance kinetics and calculation of elimination half-life.
• Estimation of first-pass metabolism based on pharmacokinetic data.

Main Results:

• Peak amitriptyline plasma concentrations varied between 10.8–43.7 ng/ml.
• Amitriptyline elimination followed biphasic, first-order kinetics with a mean half-life of 36.1 hours.
• An estimated 60% of amitriptyline underwent first-pass metabolism.
• Significant levels of the metabolite nortriptyline were detected (peak 5.9–12.3 ng/ml).

Conclusions:

• Amitriptyline exhibits a long elimination half-life and substantial first-pass metabolism.
• The formation of active nortriptyline is a significant factor in amitriptyline's overall effect.
• These pharmacokinetic findings have implications for clinical dosing and patient management.